1346.4p -2.0 -0.1%
Last Trade - 16/04/21
| Market Cap | £67.84bn |
| Enterprise Value | £94.84bn |
| Revenue | £34.10bn |
| Position in Universe | 24th / 1818 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 23,923 | 27,889 | 30,186 | 30,821 | 33,754 | 34,099 | 33,786 | 35,535 | +7.3% | ||
| -16.4 | -40.1 | +189.1 | -9.8 | +58.6 | -28.2 | +3.41 | +11.4 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | December 6, 1999 |
| Public Since | May 22, 1972 |
| No. of Shareholders: | 103,528 |
| No. of Employees: | 94,066 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE4GD UK 50, FTSE All Share , FTSE All-share - Health Care Price Return Gbp End Of Day, FTSE All-share - Pharmaceuticals & Biotechnology Price Return Gbp End Of Day, FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 100 , FTSEurofirst 300 , FTSEurofirst 300 Ex Eurozone, FTSE 350 Higher Yield , FTSE 350 , FTSE Global 100, FTSE 350 Pharmaceuticals & Biotechnology , FTSE 100 , FTSE Techmark All Share , , , |
| Exchange | London Stock Exchange (Full) |
| Shares in Issue | 5,031,388,440 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | G S K House 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom |
| Web | https://www.gsk.com/ |
| Phone | +44 20 80475000 |
| Contact | () |
| Auditors | Deloitte LLP |
As of 16/04/21, shares in GlaxoSmithKline are trading at 1346.4p, giving the company a market capitalisation of £67.84bn. This share price information is delayed by 15 minutes.
Shares in GlaxoSmithKline are currently trading at 1346.4p and the price has moved by -14.11% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the GlaxoSmithKline price has moved by -32.8% over the past year.
Of the analysts with advisory recommendations for GlaxoSmithKline, there are there are currently 5 "buy" , 14 "hold" and 0 "sell" recommendations. The overall consensus recommendation for GlaxoSmithKline is Hold. You can view the full broker recommendation list by unlocking its StockReport.
GlaxoSmithKline is scheduled to issue upcoming financial results on the following dates:
The GlaxoSmithKline dividend yield is 5.93% based on the trailing twelve month period.
Last year, GlaxoSmithKline paid a total dividend of 0.8, and it currently has a trailing dividend yield of 5.93%. Looking ahead, GlaxoSmithKline has not announced an ex-dividend date yet.
GlaxoSmithKline has yet to annouce their ex-dividend date. The historic dividend yield on GlaxoSmithKline shares is currently 5.93%.
To buy shares in GlaxoSmithKline you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in GlaxoSmithKline are currently trading at 1346.4p, giving the company a market capitalisation of £67.84bn.
Here are the trading details for GlaxoSmithKline:
Based on an overall assessment of its quality, value and momentum, GlaxoSmithKline is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in GlaxoSmithKline are currently priced at 1346.4p. At that level they are trading at 13.61% discount to the analyst consensus target price of 1,558.51.
Analysts covering GlaxoSmithKline currently have a consensus Earnings Per Share (EPS) forecast of 1.00677 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GlaxoSmithKline. Over the past six months, the relative strength of its shares against the market has been -20.12%. At the current price of 1346.4p, shares in GlaxoSmithKline are trading at -4.29% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The GlaxoSmithKline PE ratio based on its reported earnings over the past 12 months is 13.85. The shares are currently trading at 1346.4p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
GlaxoSmithKline's management team is headed by:
Here are the top five shareholders of GlaxoSmithKline based on the size of their shareholding:
